CO6300936A2 - Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores - Google Patents

Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores

Info

Publication number
CO6300936A2
CO6300936A2 CO10071046A CO10071046A CO6300936A2 CO 6300936 A2 CO6300936 A2 CO 6300936A2 CO 10071046 A CO10071046 A CO 10071046A CO 10071046 A CO10071046 A CO 10071046A CO 6300936 A2 CO6300936 A2 CO 6300936A2
Authority
CO
Colombia
Prior art keywords
animal
procedure
cardiopatia
adrenoceptors
revert
Prior art date
Application number
CO10071046A
Other languages
English (en)
Inventor
Gerarld Beddies
Axel Schmidt
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CO6300936A2 publication Critical patent/CO6300936A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un procedimiento para revertir la remodelación cardiaca electrofisiológica de animales con cardiopatía. Más específicamente, el procedimiento incluye administrar a un animal que lo necesite un bloqueante de adrenoceptores ß.
CO10071046A 2007-12-27 2010-06-11 Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores CO6300936A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1689107P 2007-12-27 2007-12-27

Publications (1)

Publication Number Publication Date
CO6300936A2 true CO6300936A2 (es) 2011-07-21

Family

ID=40456577

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10071046A CO6300936A2 (es) 2007-12-27 2010-06-11 Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores

Country Status (19)

Country Link
US (1) US20100305213A1 (es)
EP (1) EP2234609A1 (es)
JP (1) JP2011507918A (es)
KR (1) KR20100102640A (es)
CN (1) CN101909612A (es)
AU (1) AU2008342250A1 (es)
BR (1) BRPI0821483A2 (es)
CA (1) CA2710665A1 (es)
CO (1) CO6300936A2 (es)
CR (1) CR11501A (es)
EC (1) ECSP10010249A (es)
IL (1) IL205870A0 (es)
MX (1) MX2010006443A (es)
NI (1) NI201000096A (es)
RU (1) RU2010131022A (es)
SV (1) SV2010003595A (es)
TW (1) TW200942227A (es)
WO (1) WO2009083177A1 (es)
ZA (1) ZA201003867B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113148A1 (zh) * 2012-01-30 2013-08-08 Lin Shuguang β3肾上腺素受体阻滞剂的抗肿瘤用途
PT3265126T (pt) 2015-03-03 2021-08-30 Saniona As Formulação combinada de tesofensina e metoprolol
US11235029B2 (en) 2017-03-09 2022-02-01 Temple University-Of The Commonwealth System of Higher Methods for treating heart failure with a TRKB agonist
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
CN110269938A (zh) * 2019-06-27 2019-09-24 山东省眼科研究所 一种减轻铜绿假单胞菌性角膜炎症的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung

Also Published As

Publication number Publication date
ZA201003867B (en) 2011-08-31
NI201000096A (es) 2011-03-23
KR20100102640A (ko) 2010-09-24
MX2010006443A (es) 2010-09-03
AU2008342250A1 (en) 2009-07-09
WO2009083177A1 (en) 2009-07-09
EP2234609A1 (en) 2010-10-06
RU2010131022A (ru) 2012-02-10
IL205870A0 (en) 2010-11-30
ECSP10010249A (es) 2010-07-30
US20100305213A1 (en) 2010-12-02
JP2011507918A (ja) 2011-03-10
TW200942227A (en) 2009-10-16
CA2710665A1 (en) 2009-07-09
CN101909612A (zh) 2010-12-08
CR11501A (es) 2010-11-12
SV2010003595A (es) 2011-01-14
BRPI0821483A2 (pt) 2015-06-16

Similar Documents

Publication Publication Date Title
CY1123255T1 (el) Σχημα δοσολογιας για εναν αγωνιστη υποδοχεα s1p
CY1122964T1 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
ECSP11010831A (es) Compuestos orgánicos para la cicatrización de heridas
AR054566A1 (es) Tratamientoombinado de los tumores que expresan el her
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PA8852901A1 (es) Inhibidores de proteina cinasa
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
CR20110166A (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
CL2008002110A1 (es) Procedimiento para la modulacion del receptor acoplado a la proteina g gpr119 para administrar un compuesto derivado de piridinona y opcionalmente un agente terapeutico opcional para tratar diabetes mellitus.
CY1112722T1 (el) Μυκητοκτονες συνθεσεις
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
EA201290208A1 (ru) Способ лечения андроген-рецептор позитивных раковых заболеваний
CL2012001961A1 (es) Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos.
BR112019004449A2 (pt) heparina biossintética
CL2015000289A1 (es) Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado.
CO6300936A2 (es) Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores
CR11810A (es) Compuestos de 1,2-benzotiazolo utiles para combatir plagas animales
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
AR078309A1 (es) Metodo para el diagnostico de esteatohepatitis no alcoholica basado en un perfil metabolomico
CR20140075A (es) Métodos terapéuticos
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition

Legal Events

Date Code Title Description
FA Application withdrawn